Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by Pfizer" The following 200 pages are in this category, out of approximately 240 total. This list may not reflect recent changes .
Pfizer is part of major stock indices like the S&P 100 and S&P 500, having major institutional investors. [4] Pfizer is one of the top pharmaceutical companies in the United States, with a market capitalization of $150.35 billion as of December 31, 2024. It ranks fifth among U.S. pharma companies.
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
This category reflects the organization of Anatomical Therapeutic Chemical Classification System code D. Generally, drugs outlined within the ATC code D should be ...
In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. [9]In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics ...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania.The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
Parke-Davis is a subsidiary of the pharmaceutical company Pfizer. Although Parke, Davis & Co. is no longer an independent corporation, it was once America's oldest and largest drug maker, and played an important role in medical history. In 1970 Parke-Davis was acquired by Warner–Lambert, which in turn was acquired by Pfizer in 2000. [2]
An online version is available, with all drug listings available to view for free. Concise drug monographs form the core of MIMS; these include safety information, details of the active ingredient, presentation, price, indication, dosage and manufacturer. In addition, the book includes drug comparison tables, and summaries of clinical guidance.